Accurate de novo design of high-affinity protein binding macrocycles using deep learning
Stephen Rettie,David Juergens,Victor Adebomi,Yensi Flores Bueso,Qinqin Zhao,Alexandria Leveille,Andi Liu,Asim Bera,Joana Wilms,Alina Üffing,Alex Kang,Evans Brackenbrough,Mila Lamb,Stacey Gerben,Analisa Murray,Paul Levine,Maika Schneider,Vibha Vasireddy,Sergey Ovchinnikov,Oliver Weiergräber,Dieter Willbold,Joshua Kritzer,Joseph Mougous,David Baker,Frank DiMaio,Gaurav Bhardwaj
DOI: https://doi.org/10.1101/2024.11.18.622547
2024-11-18
Abstract:The development of macrocyclic binders to therapeutic proteins has typically relied on large-scale screening methods that are resource-intensive and provide little control over binding mode. Despite considerable progress in physics-based methods for peptide design and deep-learning methods for protein design, there are currently no robust approaches for de novo design of protein-binding macrocycles. Here, we introduce RFpeptides, a denoising diffusion-based pipeline for designing macrocyclic peptide binders against protein targets of interest. We test 20 or fewer designed macrocycles against each of four diverse proteins and obtain medium to high-affinity binders against all selected targets. Designs against MCL1 and MDM2 demonstrate KD between 1-10 uM, and the best anti-GABARAP macrocycle binds with a KD of 6 nM and a sub-nanomolar IC50 in vitro. For one of the targets, RbtA, we obtain a high-affinity binder with KD < 10 nM despite starting from the target sequence alone due to the lack of an experimentally determined target structure. X-ray structures determined for macrocycle-bound MCL1, GABARAP, and RbtA complexes match very closely with the computational design models (RMSD < 2 Å). In contrast to library screening approaches for which determining binding mode can be a major bottleneck, the binding modes of RFpeptides-generated macrocycles are known by design, which should greatly facilitate downstream optimization. RFpeptides thus provides a powerful framework for rapid and custom design of macrocyclic peptides for diagnostic and therapeutic applications.
Biochemistry